Simultaneously, FMT modulates the proportion of T-cell subsets, decreasing Th17 cells and IL-17A levels, thereby inhibiting the release of pro-inflammatory factors and angiogenic mediators, and disrupting the formation of the HCC microenvironment[11]. This evidence concerns the gene IL17A and hepatocellular carcinoma.